Biotin-Acridine Red Cell Exchange Kinetics
NCT: NCT07155031 · WITHDRAWN
Brief Summary
The primary objective of the study is to describe the recovery and survival of pathogen-reduced (PR) red blood cells (RBCs) prepared and stored with the INTERCEPT Blood System for RBCs® (hereafter referred to as INTERCEPT RBCs) in patients with sickle cell disease (SCD) undergoing red cell exchange (RCE) therapy, utilizing flow cytometry for biotin and acridine RBC surface markers.
Frequently Asked Questions
What is Biotin-Acridine Red Cell Exchange Kinetics?
Biotin-Acridine Red Cell Exchange Kinetics is a clinical trial registered under NCT07155031. Current status: WITHDRAWN.
What is the status of NCT07155031?
The current status of NCT07155031 (Biotin-Acridine Red Cell Exchange Kinetics) is: WITHDRAWN.
When did Biotin-Acridine Red Cell Exchange Kinetics start?
Biotin-Acridine Red Cell Exchange Kinetics started on 2025-10-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.